Vol. 18 No. 3, March 2008

Neuromuscular disorders : NMD (IM) v. 18, no. 3 (Mar. 2008) General Collection W1 NE337GB 2008-05-08 00008-37



18 (3) 193–276 ISSN 0960-8966

Neuromuscular Disorders

Editor-in-Chief

V Dubowitz UK

Associate Editors


A G Engel USA

L Merlini Italy

A Oldfors Sweden

F M S Tomé France

T Voit France





This material **Official** Journal of the World Muscle Society at the NLM and may be Subject US Copyright Laws



© 2008 Elsevier B.V. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier B.V., and the following terms and conditions apply to their use:

Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier's Rights Department: phone (+1) 215 239 3804; fax (+1) 215 239 3805, e-mail: healthpermissions/a/elsevier.com. Requests may also be completed on-line via the Elsevier homepage (http://www.elsevier.com/locate/ permissions).

In the USA, users may clear permissions and make payment through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (+1) (978) 7508400, fax: (+1) (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London WIP 0LP, UK; phone: (+44) 20 7631 5555; fax: (+44) 20 7631 5500. Other countries may have a local reprographic rights agency for payments.

Derivative Works

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution.

Permission of the Publisher is required for all other derivative works, including compilations and translations.

Electronic Storage or Usage

Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article.

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Address permissions requests to: Elsevier Rights Department, at the fax and e-mail addresses noted above.

Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer

Author enquiries

For enquiries relating to the submission of articles (including electronic submission where available) please visit http://www.elsevier.com/locate/guidepublication. Register for free to receive email updates from the article tracking service at http://www.elsevier.com/trackarticle Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided after registration of an article for publication.

Neuromuscular Disorders proceeds entirely online at www.ees.elsevier.com/nmd

There is an online tutorial for authors and online support for technical problems or questions via Elsevier's AuthorSupport team (authorsupport@elsevier.com).

Publication information: Neuromuscular Disorders (ISSN 0960-8966). For 2008 Volume 18 is scheduled for publication. Subscription prices are available upon request from the Publisher, Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by surface mail except to the following countries where air delivery by SAL mail is ensured: Argentina, Australia, Brazil, Canada, Hong Kong, India, Israel, Japan, Malaysia, Mexico, New Zealand, Pakistan, PR China, Singapore, South Africa, South Korea, Taiwan, Thailand, USA. For all other countries airmail rates are available upon request. Claims for missing issues should be make within six months of our publication (mailing) date.

Orders, claims, and product enquiries: Please contact the Customer Service Department at the Regional Sales Office nearest your

Orlando	Amsterdam	Tokyo	Singapore
Elsevier	Elsevier	Elsevier	Elsevier
Customer Service Department	Customer Service Department	Customer Service Department	Customer Service Department
6277 Sea Harbor Drive	P.O. Box 211	4F Higashi-Azabu, 1-Chome Bldg	3 Killiney Road
Orlando, FL 32887-4800, USA	1043 NX Amsterdam	1-9-15 Higashi-Azabu, Minato-ku,	#08-01 Winsland House I
Tel.: (+1) (877) 8397126 [toll free number	The Netherlands	Tokyo 106-0044, Japan	Singapore 239519
for US customers], or (+1) (407) 3454020	Tel.: (+31) (20) 4853757	Tel.: (+81) (3) 5561-5037	Tel.: (+65) 63490222
[customers outside US]	Fax: (+31) (20) 4853432	Fax: (±81) (3) 5561 5047	Fax: (+65) 67331510
Fax: (+1) (407) 3631354	e-mail: nlinfo-f@elsevier.com	e-mail: jp.info@elsevier.com	e-mail: asiainfora elsevier.com
e-mail: usjes@elsevier.com		71	

The Instructions to Authors can be found on the journal's website www.elsevier.com/locate/nmd.

Neuromuscular Disorders has no page charges

PERIODICALS POSTAGE PAID at Rahway, New Jersey. Neuromuscular Disorders (ISSN 0960-8966) is published monthly by Elsevier B.V., 1000 AE Amsterdam, The Netherlands.

The annual subscription in the USA is \$1,214 per year.

Neuromuscular Disorders is circulated by Mercury International Limited, 365 Blair Road, Avenel, NJ 07001, USA.

POSTMASTER: Please send address corrections to Neuromuscular Disorders, c/o Customer Services, Elsevier Inc., 655 Avenue of the Americas, New York, NY 10010 USA.

Advertising information: Advertising orders and enquiries can be sent to: USA, Canada and South America: Mr. Tino DeCarlo, The Advertising Department, Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710, USA; phone: (+1) (212) 633-3815; fax; (+1) (212) 633-3820, c-mail + decarlo a elsevier com Japan: The Advertising Department, Elsevier K.K., 4F Higashi-Azabu, I-Chome Bldg, I-9-15 Higashi-Azabu, Minato-ku, Tokyo 106 0044, Japan, phone. (184) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: jp.info@elsevier.com. Europe and ROW: Commercial Sales Department, Elsevier Ltd., The Boulevard, Langtord Lane, Kidlington, Oxford OX5 IGB, UK; phone: (+44) 1865 8430 Midsawateria) was Caldiago Carrier in mediago escription

at the NLM and may be

Subject US Copyright Laws



Neuromuscular Disorders

Volume 18 Number 3

Cited in: Current Contents/Life Sciences, Elsevier BIOBASE/Current Awaren Index Medicus, MEDLINE, Neuroscience Citation Index, Reference Up Science Citation Index, SciSearch CONTENTS



NLM 03105054 1

Research papers	
Hand weakness in Duchenne muscular dystrophy and its relation to physical disability F.L. Mattar, C. Sobreira	193
Natural history of CMT1A including QoL: A 2-year prospective study L. Padua, D. Pareyson, I. Aprile, T. Cavallaro, A. Quattrone, N. Rizzuto, G. Vita, P. Tonali, A. Schenone	199
Novel mitochondrial tRNA ^{Leu(CUN)} transition and D4Z4 partial deletion in a patient with a facioscapulohumeral phenotype M. Filosto, P. Tonin, M. Scarpelli, C. Savio, F. Greco, M. Mancuso, G. Vattemi, V. Govoni, N. Rizzuto, R. Tupler, G. Tomelleri	204
Differential diagnosis of muscular hypotonia in infants: The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) U. Yiş, E. Dirik, C. Chambaz, B. Steinmann, C. Giunta	210
Expression of caveolar components in primary desminopathy A. Shinde, S. Nakano, M. Sugawara, I. Toyoshima, H. Ito, K. Tanaka, H. Kusaka	210
GABAergic miniature spontaneous activity is increased in the CA1 hippocampal region of dystrophic mdx mice L. Graciotti, A. Minelli, D. Minciacchi, A. Procopio, G. Fulgenzi	210

Microarray analysis of mdx mice expressing high levels of utrophin: Therapeutic implications for dystrophin deficiency D. Baban, K.E. Davies	239
Adenovirus and adeno-associated virus- mediated delivery of human myophos- phorylase cDNA and LacZ cDNA to muscle in the ovine model of McArdle's disease: Expression and re-expression of glycogen phosphorylase	
J.McC. Howell, K.R. Walker, L. Davies, E. Dunton, A. Everaardt, N. Laing, G. Karpati	248
Workshop reports	
155th ENMC workshop: Polymerase gamma and disorders of mitochondrial DNA synthesis, 21–23 September 2007, Naarden, The Netherlands P.F. Chinnery, M. Zeviani	259
149th ENMC International Workshop and 1st TREAT-NMD Workshop on: "Planning Phase I/II Clinical trials using Systemically Delivered Antisense Oligonucleotides in Duchenne Muscular Dystrophy" F. Muntoni, K.D. Bushby, G. van Ommen	268
Letter to the Editor	
Genotype-phenotype analysis in patients with giant axonal neuropathy G. Kuhlenbäumer	276
Update in Neuromuscular Disorders	
wwws online application form	יי
WMS - 13th International Congress	iv/

NMD Gene Table is published:

(blockade of TNF) treatment

- online at http://www.musclegenetable.org

Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q

H.G. Radley, M.J. Davies, M.D. Grounds

- last printed issue NMD 18/1. This print version is also freely available at http://www.journals.elsevierhealth.com/periodicals/nmd

227



00973

١V



Forthcoming meetings



Neuromuscular Disorders 18 (2008) 268-275



Workshop report

149th ENMC International Workshop and 1st TREAT-NMD Workshop on: "Planning Phase I/II Clinical trials using Systemically Delivered Antisense Oligonucleotides in Duchenne Muscular Dystrophy"

Francesco Muntoni ^{a,*}, Kate D. Bushby ^b, Gertjan van Ommen ^c

* Dubowitz Neuromuscular Centre, Institute of Child Health & Great Ormond Street Hospital, 30 Guilford Street, London WCIN 1EH, UK
b Institute of Human Genetics, International Centre for Life, Newcastle upon Tyne, UK
c Leiden University Medical Center, Leiden, The Netherlands

Received 15 November 2007

Keywords: Antisense oligonucleotides; Duchenne muscular dystrophy; Therapeutic trials; Exon skipping

1. Introduction

Thirty-one participants from 7 countries (Australia; England; France; Germany; Italy; The Netherlands; USA) attended the second ENMC workshop on antisense oligonucleotides in Duchenne muscular Dystrophy (DMD). The topic of this workshop was on "Planning Phase I/II Clinical Trials Using systemically delivered Antisense Oligonucleotides in Duchenne Muscular Dystrophy (DMD)" and followed a similar workshop held in 2004 focused on intramuscular administration of antisense oligonucleotides or AONs. The workshop was organized with the support of the TREAT-NMD EU Network of Excellence (www.treat-nmd.eu) and Parent Project Muscular Dystrophy (PPMD), and was attended by representative of the two companies involved in the current intramuscular injection trials, Prosensa for the 2-O-methyl phosphorothioate RNA modified and AVI Biopharma for the phosphorodiamidate morpholino oligomers (PMOs or more commonly "morpholinos"). Although, the PMO backbone is based on synthetic subunits, not regular nucleotides, for the sake of simplicity we will refer to all antisense oligomers as AONs.

0960-8966/\$ - see front matter © 2007 Elsevier B.V. All rights reserved. doi:10.1016/j.nmd.2007.11.010

Specific aims of the meeting were for 2 consortia, one from the Netherlands and one from England, currently involved in intramuscularly administered AON trials, to present the progress of their respective studies; and for members of these consortia and representatives from other international groups at different planning stages of the use of AONs in DMD, to discuss various aspects related to the best strategies to plan future systemic AON trials. Issues discussed also included methodological issues on the different backbone of the AONs used (2-O-methyl phosphorothioate modified [2OMePS] and morpholino) oligomers; safety, regulatory, and ethical aspects.

DMD is a severe muscle wasting condition with onset in early childhood, progressive muscle weakness and disability and ultimately reduced life expectancy. It is caused by mutations in the DMD gene that lead to the failure to produce the corresponding muscle protein called dystrophin. Most of these mutations are out-of-frame deletions. Laboratory studies over the last decade have shown that the addition of small molecules named antisense oligonucleotides or oligomers (AONs) to cultured patient muscle cells, and their injection into muscles of the *mdx* mouse model for DMD can restore the production of the protein dystrophin [1,2]. Although this correction is only temporary, it induces improved function of the patient cells and mouse muscle. More recently, the repeated systemic (intravenous) administration of AONs was shown

This material was copied



^{*} Corresponding author, Tel.: ±44-208-383-3295; fax: ±44-208-7462187, E-mail address: f.muntoni@ich.ucl.ac.uk (F. Muntoni).

to be capable of restoring a sustained dystrophin expression in the mouse model of DMD, and this was followed by a significant functional improvement of the mouse muscle function [3–6]. If safe and equally effective in people, the repeated systemic administration of AONs could therefore be an effective tool to slow down the disease progression in DMD boys.

2. Phase I/Ha trials on intramuscular AON administration

Two representatives of the Dutch Consortium, Jan Verschuuren and Judith van Deutekom, presented the data of the recently completed IM injection trial of a 20MePS AON to induce skipping of exon 51, funded by the Dutch Duchenne Parent Project, SenterNovem (funded by the Department of Economic Affairs) and ZonMw (Dutch MRC, funded by the Department of Health) and Association Française contre les Myopathies (AFM) and sponsored by Prosensa. This study was aimed at defining safety and local dystrophin restoration of IM administered 20MePS AON in a single muscle in DMD boys [7]. As part of the pre-screening program, boys had a muscle MRI to document adequate preservation of the target muscle, the tibialis anterior (which was invariably the least affected muscle in the lower leg of affected boys), and a skin biopsy for MyoD transfection and myogenic conversion of fibroblasts and in vitro testing of response to the administration of AON. Four boys were included between the age of 10 and 13, carrying deletions of exons 50, 52, 48 50 and 49-50. They received a single dose of 0.8 mg of the 20MePS exon 51 AON in one tibialis anterior muscle using an EMG guided needle. A muscle biopsy of the same tibialis anterior was performed 4 weeks after the injection of the AON and dystrophin protein and transcript analysed in detail. The results in all 4 boys were extremely encouraging with robust levels of dystrophin skipped transcript visible I month after the AON injection, and the percentage of dystrophin positive fibres in the tibialis anterior biopsy comprised between 64% and 97% in the 4 children studied. In view of the unequivocal positive results in these 4 patients, the decision was made not to recruit additional patients into this study original plans were to recruit a total of 4 6 DMD boys. Reassuringly the intramuscular administration of the 20MePS was well tolerated with no apparent inflammatory response to the administration of the AON.

Two representatives of the MDEX consortium, France-sco Muntoni and Maria Kinali, illustrated the status of the study in UK. This study is funded by the Department of Health, sponsored by Imperial College and run in collaboration with AVI Biopharma. This study is similar to the Dutch trial, the main differences being that (i) the AON injected will be a 30mer morpholino, (ii) the study is a dose escalation study; (iii) one extensor digitorum brevis (EDB) of older children (12–17 yrs) will receive the PMO AON administration while the contralateral EDB will receive a sham injection. At the end of the study an open biopsy will

be performed on both muscles to allow quantitation and differentiation of dystrophin production following the administration of the AONs from the background of dystrophin that the patient might produce, including revertant fibres. Nine DMD boys will be studied, three receiving the lowest dose, 3 an intermediate dose and 3 the highest dose, with the recruitment of this latter group only considered in case the results from the previous patient groups are equivocal. A muscle MRI protocol has been devised to pre-screen patients in order to confirm the preservation of the EDB, and preparatory studies have indicated that most DMD boys up to the age of 16 have sufficiently well preserved EDB muscle to be eligible for the study. Also the MDEX consortium protocol requires for each patient to be studied by MyoD transfection of skin fibroblasts and subsequent AON treatment to confirm feasibility of AON-induced dystrophin restoration in vitro; in addition a detailed neuropsychiatric questionnaire was devised in order to be able to monitor expectations and impact of the trial on individuals. At the time of the workshop the study was in the process of completing regulatory authorization.

As part of the preparatory studies, the MDEX consortium has studied whether revertant fibres increase with age in DMD boys. Previous studies performed in the mdx mouse have suggested that this could be the case. Twelve boys who have had a muscle biopsy at diagnosis and which was available for further evaluation were recruited into this study; these boys had muscle biopsies during planned surgical procedures of either the EDB muscles (9 cases) or paraspinal muscles (3 cases) on average 7 years following the original diagnostic quadriceps muscle biopsy. In none of these 12 patients was there an increase of the frequency of revertant fibres with age, at least as far as the studied muscles were concerned. This information is helpful as it suggests that any dystrophin produced following the AON administration is the likely result of the AON-induced exon skipping and not naturally occurring revertants, provided that the number of revertants in the original muscle biopsy is negligible (a threshold of 5% was arbitrarily agreed).

3. Preclinical studies focused on systemic AON administration

Judith van Deutekom presented the recent results of the systemic administration of a 2OMePS AON against exon 23 in the *mdx* mouse. These studies focused on different mode of administration (IV, subcutaneous [SC]; intraperitoneal [IP]) and results were validated not only using semiquantitative assays, but also by an AON-specific hybridization assay to measure tissue levels of 2OMePS AON. This method developed by Prosensa allowed assessment of the biodistribution of the 2OMePS in a number of organs (including liver and kidney) serum and muscle. While there were significant differences in the pharmacokinetics of the AON in several organs following

This material was copied



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

